相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules
Adam Szpechcinski et al.
CANCER LETTERS (2016)
Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas
Andreas W. Berger et al.
GASTROENTEROLOGY (2016)
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Sabrina Arena et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Jeanne Tie et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
J. Tie et al.
ANNALS OF ONCOLOGY (2015)
Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
A. Szpechcinski et al.
BRITISH JOURNAL OF CANCER (2015)
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
Josep Tabernero et al.
LANCET ONCOLOGY (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
Karen Lise Garm Spindler et al.
PLOS ONE (2015)
Detection of Circulating Pancreas Epithelial Cells in Patients With Pancreatic Cystic Lesions
Andrew D. Rhim et al.
GASTROENTEROLOGY (2014)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Alain R. Thierry et al.
NATURE MEDICINE (2014)
Detection of Methylated Septin 9 in Tissue and Plasma of Colorectal Patients with Neoplasia and the Relationship to the Amount of Circulating Cell-Free DNA
Kinga Toth et al.
PLOS ONE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma
Karen-Lise G. Spindler et al.
ACTA ONCOLOGICA (2013)
BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel
D. Gonzalez et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
ALK in Lung Cancer: Past, Present, and Future
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
Implementing personalized cancer genomics in clinical trials
Richard Simon et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox Point
Manish R. Sharma et al.
CANCER RESEARCH (2012)
EMT and Dissemination Precede Pancreatic Tumor Formation
Andrew D. Rhim et al.
CELL (2012)
Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
Karen-Lise Garm Spindler et al.
CLINICAL CANCER RESEARCH (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
Tim Forshew et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Cell-free DNA in the blood as a solid tumor biomarker-A critical appraisal of the literature
Klaus Jung et al.
CLINICA CHIMICA ACTA (2010)
Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts
Alain R. Thierry et al.
NUCLEIC ACIDS RESEARCH (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer
M. Frattini et al.
CANCER LETTERS (2008)
Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107
Axel Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
Axel Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance
Emmanuelle Gormally et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2007)
Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines
H Sorbye et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
RC Bast et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
